2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3408 Exposure-response analysis and quantitative systems pharmacology modeling for recommended phase 3 dose selection of revumenib in newly diagnosed AML

Enoch Cobbina, PhD, MS, Joshua Stewart, BS2, YuWei Lin, PhD3, Amanda Wang, MD4, Cameron Meaney5, Ashley Markazi6, Bradley D. Hunter7, Ghayas C. Issa, MD8, Angela R. Smith, MD9, Ophelia Yin, PhD10
1 Syndax Pharmaceuticals, Inc., New York, New York, United States
2 Syndax Pharmaceuticals, Inc., New York, New York, United States
3 Certara Drug Development Solutions, Princeton, New Jersey, United States
4 Certara Drug Development Solutions, Princeton, New Jersey, United States
5 Simulations Plus, Inc., Research Triangle Park, North Carolina, United States
6 Simulations Plus, Inc., Research Triangle Park, North Carolina, United States
7 Intermountain Health, Salt Lake City, Utah, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 Syndax Pharmaceuticals, Inc., New York, New York, United States
10 Syndax Pharmaceuticals, Inc., New York, New York, United States

Introduction: Revumenib is a first-in-class, oral, potent, and selective inhibitor of the menin-KMT2A interaction. Revumenib is used for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with an NPM1 mutation (NPM1m) or R/R acute leukemia with a KMT2A translocation. Revumenib in combination with standard-of-care intensive chemotherapy (IC) is under investigation for the treatment of newly diagnosed AML. Here, we present quantitative analyses, including exposure-response (E-R) analyses and quantitative systems pharmacology (QSP) modeling, to support dose selection and provide a rationale for the revumenib dose in combination with IC.

 Methods: A pooled pharmacokinetic (PK) dataset comprising 397 patients (pts) was used to develop a population PK (PopPK) model, incorporating data from the AUGMENT-101 monotherapy study (n=335; NCT04065399) and two combination studies: AUGMENT-102 (revumenib plus fludarabine and cytarabine, n=27; NCT05326516) and SNDX-5613-0708 (revumenib plus daunorubicin or idarubicin and cytarabine, n=35; NCT06226571). In AUGMENT-101, revumenib doses ranged from 113–339 mg q12h or three times daily. In the combination studies, two dose levels (DL) were evaluated: DL1 (110 mg q12h with a strong CYP3A4 inhibitor [CYP3A4i] or 220 mg q12h without) and DL2 (160 mg q12h with a strong CYP3A4i or 270 mg q12h without). Exposures of revumenib and its primary metabolite, M1, were estimated using the PopPK model, and E-R relationships were evaluated using logistic regression. E-R efficacy analyses were based on data from SNDX-5613-0708 only and included complete remission (CR), measurable residual disease (MRD)-negative CR, and overall response rate (ORR). E-R safety analyses used pooled data from the monotherapy and combination studies, with a sensitivity analysis restricted to combination studies. A total of 13 safety endpoints were assessed. Additionally, QSP modeling was conducted to predict rates of cytopenias in pts with newly diagnosed NPM1m AML receiving revumenib in combination with IC. The QSP model integrated AML disease biology, key mutational profiles (NPM1, FLT3, and KMT2A rearrangements), and revumenib preclinical PK/pharmacodynamic, and clinical PK, efficacy, and safety data.

 Results: The PopPK model indicated dose-proportional increases in revumenib and M1 exposure. Within each DL, exposures were comparable between monotherapy and combination settings, suggesting that concomitant IC does not affect revumenib PK. More than 84% of pts at DL1 and more than 92% of pts at DL2 were predicted to achieve average concentrations exceeding the target threshold (menin–KMT2A IC90) associated with maximal antileukemic effect. No clear E-R relationships were observed for CR, MRD-negative CR, or ORR (all P>0.05), likely reflecting the high response rates observed across exposure levels. Statistically significant (P<0.05) but shallow E-R relationships were identified for selected safety endpoints, including treatment-emergent adverse events (TEAEs) leading to dose modification, TEAEs leading to discontinuation, and QTcF prolongation (any grade and grade ≥3). Predicted increases in these safety events from DL1 to DL2 were small (1.2%–4.2%) with overlapping confidence intervals, suggesting no clinically meaningful difference. When analyses were restricted to combination studies, no statistically significant E-R relationships were observed for any safety endpoint (all P>0.05). QSP modeling further predicted nearly identical rates of anemia, neutropenia, and thrombocytopenia between DL1 and DL2 in the combination setting.

 Conclusion: PopPK modeling predicted that, relative to DL1, more pts at DL2 would achieve average revumenib concentrations above the menin–KMT2A IC90, an important measure associated with maximal leukemic control and suppression of MEN1 acquired resistance mutations, based on preclinical evidence. E-R analyses demonstrated a broad therapeutic margin for revumenib across monotherapy and combination therapy settings, with higher exposures showing no clinically meaningful increases in safety risk. QSP modeling showed no difference in cytopenia rates between dose levels in the combination setting. The totality of these analyses support the selection of DL2 (revumenib 160 mg q12h with a strong CYP3A4i or 270 mg q12h without a strong CYP3A4i) as the recommended phase 3 dose in combination with IC for pts with newly diagnosed AML for the upcoming phase 3 REVEAL-ND study (NCT07211958).

Enoch Cobbina, PhD, MS: Syndax Pharmaceuticals, Inc. - Stock (publicly traded); Syndax Pharmaceuticals, Inc. - Current Employment